Skip to main content
PEN
NYSE Industrial Applications And Services

Penumbra Tops Q2 Revenue, but Merger Costs and Taxes Erode Net Income

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$319.83
Mkt Cap
$12.579B
52W Low
$221.26
52W High
$362.41
52W Position info
45% above low
Off High info
12% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

PEN sits 45% above its 52-week low of $221.26.

Summary

Penumbra's Q2 revenue of $390M edged past estimates, but net income dropped 23% as merger-related costs and a higher tax rate offset strong sales growth.


Key Events · Earnings and Guidance · PEN

  • Q2 Revenue Beats Consensus

    Revenue rose 14.9% to $390.0 million, slightly above the $389 million consensus, with embolization and access up 20% and thrombectomy up 12.5%.

  • Net Income Drops 23%

    Net income fell to $34.8 million from $45.3 million a year ago, pressured by $6.9 million in acquisition-related costs and a higher effective tax rate.

  • Gross Margin Improves

    Gross margin expanded to 67.9% from 66.0% in Q2 2025, reflecting favorable product mix and operating leverage.

  • Guidance Withdrawn Amid Merger

    Penumbra will not provide full-year 2026 guidance or host an earnings call, citing the pending acquisition by Boston Scientific.


Analysis · PEN · Industrial Applications And Services

Penumbra posted a solid top-line beat, with revenue climbing 14.9% to $390 million on the back of 20% growth in embolization and access. Yet net income contracted 23% year-over-year, as $6.9 million in acquisition-related costs tied to the pending Boston Scientific merger and a higher tax rate more than offset the revenue gains. Management is withholding guidance and skipping the earnings call, citing the pending acquisition—a clear sign that closing the deal, not near-term operations, is the priority. For investors, the central question is whether the merger will close as expected; the earnings report itself is a secondary event.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PEN was trading at $319.83 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $221.26 to $362.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PEN - Latest Insights

PEN
Nov 02, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $321.99
Real-time Price: $320.91 info
Change: -$1.08 (-0.34%) info
Market Cap: $12.648B info
PEN
Oct 29, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $321.97
Real-time Price: $320.91 info
Change: -$1.06 (-0.33%) info
Market Cap: $12.648B info
PEN
Oct 20, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $321.73
Real-time Price: $320.91 info
Change: -$0.820 (-0.25%) info
Market Cap: $12.648B info
PEN
Jul 30, 2026, 4:44 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $319.83
Real-time Price: $320.91 info
Change: +$1.08 (+0.34%) info
Market Cap: $12.648B info
PEN
Jul 30, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $319.83
Real-time Price: $320.91 info
Change: +$1.08 (+0.34%) info
Market Cap: $12.648B info